Allarity Therapeutics opened its fiscal 2026 as it ended the prior year: a clinical-stage oncology company with no product revenue, a shrinking cash runway, and one lead asset whose fate will be decided by clinical data, not headlines. The first quarter's small print mattered far more than its income statement. The company recorded a net loss of $2.75 million, almost identical to the $2.73 million it lost a year earlier, on revenue of just $25,000 from the licensing of its DRP testing service. The real story of the quarter was the balance sheet, not the P&L. On March 2, 2026, management borrowed $20 million from Streeterville Capital under two promissory notes - a $10 million unsecured note that netted the company about $10 million after an original issue discount, and a $10 million secured note whose proceeds sit in restricted cash as its own collateral. By quarter end the company held $29.8 million of cash and restricted cash, enough management says to fund operations for at least the next twelve months.
The quarter's other meaningful developments straddled the reporting period. In April and June the U.S. Patent and Trademark Office first allowed and then granted a patent on the stenoparib-specific DRP companion diagnostic - the test that defines the precision-medicine thesis. In May the company said the manufacturing campaign for its active pharmaceutical ingredient was progressing on schedule, and in June it presented a trial-in-progress poster for stenoparib at a European gynecological cancer meeting. None of those items generates revenue, but together they define what the company is: a roughly $22 million market-capitalization company trading at about its cash value against an option on a Phase 2 PARP/tankyrase inhibitor. The shares at $1.40 in mid-August sit well above their 52-week low of $0.81 from February, but far below the $1.97 high of September 2025 - a stock priced for a binary clinical outcome rather than a glide path.